Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control (RHIVIERA-02)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05300035 |
Recruitment Status :
Not yet recruiting
First Posted : March 29, 2022
Last Update Posted : February 1, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV/AIDS and Infections | Drug: Recombinant human monoclonal antibody (bNAbs) Drug: Placebo | Phase 2 |
The study proposes to test an intervention consisting of dual long-acting HIV-specific broadly neutralizing antibodies (3BNC117-LS & 10-1074-LS ) + ART, at primary HIV-1 infection, and to compare it to ART only regarding HIV-1 replication.
The study aims to enrol 60 participants in French (Ile-de-France) clinical centres. Participants will have been diagnosed with primary HIV-1 infection, will start ART during early phase of Primary HIV infection, and will interrupt ART 52 weeks later.
Study duration will vary by participant, depending on the time of ART interruption and the time to viral rebound.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomised Phase II Placebo-controlled Trial of Antiretroviral Therapy (ART) Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo During Primary HIV-1 Infection to Study the Impact on Post-treatment HIV Control. |
Estimated Study Start Date : | May 15, 2023 |
Estimated Primary Completion Date : | December 2026 |
Estimated Study Completion Date : | December 2028 |

Arm | Intervention/treatment |
---|---|
Active Comparator: bNAbs
ART plus dual long-acting (LS) broadly neutralising antibodies (bNAbs) infusion at HIV-1 primary HIV-1 infection, during 52 weeks minimum, followed by and Antiretroviral Treatment Interruption (ATI).
|
Drug: Recombinant human monoclonal antibody (bNAbs)
Other Name: 10-1074-LS and 3BNC117-LS |
Placebo Comparator: Placebo
ART plus placebo (saline solution) at HIV-1 primary HIV-1 infection, during 52 weeks minimum, followed by and Antiretroviral Treatment Interruption (ATI).
|
Drug: Placebo
Other Name: Saline solution |
- Proportion of participants with plasma HIV-1 RNA below 400 cp/mL 24 weeks following ATI (W24 ATI), in the confirmed absence of ART. [ Time Frame: at Week 24 of antiretroviral treatment interruption period (ATI) ]These participants will be considered as post-treatment controllers.
- Tolerance of bNAbs infusion : Number of clinical and biological adverse event (AE) [ Time Frame: from date of inclusion to the last follow-up visit date, up to 148 weeks ]Number of clinical and biological AE during follow-up. Abnormal laboratory values will be identified as those outside values defined by the DAIDS scale
- Tolerance of bNAbs infusion : Nature and Grade of clinical and biological AE [ Time Frame: from date of inclusion to the last follow-up visit date, up to 148 weeks ]Grade of clinical and biological adverse during follow-up. The intensity of all AE (serious and non-serious) will be graded using the DAIDS AE Grading Table Corrected Version 2.1-July 2017
- Tolerance of bNAbs infusion : Time of clinical and biological adverse event (AE) [ Time Frame: from date of inclusion to the last follow-up visit date, up to 148 weeks ]
- Proportion of participants resuming ART within the first 24 weeks of ART interruption, according to the reason for resuming. [ Time Frame: at Week 24 of antiretroviral treatment interruption period (ATI) ]
- Time to potential ART resumption for non-controllers. [ Time Frame: from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption date, assessed up to 48 weeks following ATI ]
- Clinical and immulogical criteria during follow-up: Proportion of participants with clinical symptoms. [ Time Frame: during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption) ]
- Clinical and immulogical criteria during follow-up: Evolution of CD4, CD8 (levels and %) and CD4/CD8 ratio. [ Time Frame: during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption) ]
- Clinical and immulogical criteria during follow-up: Evolution of inflammation markers levels. [ Time Frame: biological parameters levels during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption) ]physiological parameters levels will be studied: IP10, TGFβ, IL-7, IL-10, IL-12, IL-15, IL-18, Citrulline, sCD14, sCD163, TNF-α
- Immulogical criteria : Changes in the magnitude and quality of HIV-specific T cell responses and humoral responses. [ Time Frame: physiological parameters levels during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption) ]physiological parameters levels will be studied: frequency and functionality of T cells responding to HIV peptides measured by intracellular cytokine staining, surface expression of activation and differentiation markers, HIV suppressive capacity upon co-culture with autologous infected cells
- Virological criteria during follow-up: Plasma HIV-1 RNA and HIV-1 DNA level and cell-associated HIV RNA transcripts changes. [ Time Frame: during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption) ]
- Virological criteria : Proportion of participant with plasma HIV-1 RNA < 50 cp/mL at 12- and 24-weeks following ART interruption. [ Time Frame: at Week 12 and Week 24 of antiretroviral treatment interruption period (ATI) ]
- Virological criteria : Cumulative plasma viremia during ART interruption. [ Time Frame: from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption, assessed up to 48 weeks following ATI ]
- Virological criteria : in case of ART resumption, time from date of ART interruption begining to date of first HIV-1 RNA ≥ 50 copies/mL [ Time Frame: from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption, assessed up to 48 weeks following ATI ]
- Virological criteria : in case of ART resumption, proportion of participant with plasma HIV-1 RNA < 50 copies/mL within 24 weeks of ATI. [ Time Frame: from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption, assessed up to 48 weeks following ATI ]
- Virological criteria : Evolution of total HIV-1 DNA and cell-associated HIV-1 RNA by US q-PCR and predictive value on post- ART interruption evolution. [ Time Frame: during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption) ]
- Virological criteria : Evolution of detection proportion and level of cell-associated HIV-1 RNA. [ Time Frame: during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption) ]
- Virological criteria : Qualitative and quantitative changes in the persistent viral reservoir. [ Time Frame: physiological parameters levels during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption) ]physiological parameters levels will be studied: total cell associated HIV-DNA, integrated HIV-DNA, proportion of replication competent vs defective proviruses
- Dosages of bNAbs performed during follow-up. [ Time Frame: during ART follow-up (Week 1,Week 12, Week 24, Week 36), and antiretroviral treatment interruption period (Day 0, Week 12, Week 24) ]
- Criteria related to the risk of HIV-1 transmission : Proportion of participants reporting to use condoms during sexual intercourses [ Time Frame: from date of inclusion to the last follow-up visit date, up to 148 weeks ]
- Criteria related to the risk of HIV-1 transmission : Proportion of participants reporting to have proposed PrEP at their partners. [ Time Frame: from date of inclusion to the last follow-up visit date, up to 148 weeks ]
- Social sciences criteria : Proportion of patients satisfied with their participation and the associated factors [ Time Frame: from date of inclusion to the last follow-up visit date, up to 148 weeks ]
- Social sciences criteria : Impact of the participation in the trial on participant quality of life and quality of sexual life [ Time Frame: from date of inclusion to the last follow-up visit date, up to 148 weeks ]Through statistical analyses of some self-administered questionnaires items (in particular the SF12.v2 scale for quality of life) and thematic analyses of semi-directive individual interviews we will highlight the impact of the participation in the trial.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Confirmed primary HIV-1 infection diagnostic
- Aged ≥18 to ≤70 years old at screening
- Willing to use use an effective method of contraception from the inclusion until the end of the follow-up in the trial
- Negative plasmatic beta human chorionic gonadotropin (β-HCG) pregnancy test, when applicable
- Agree not to seek pregnancy including through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit, when applicable
- Informed and written signed consent
- Participant with regular health insurance
- Willing to accept the trial constraints (travel for IMP administration and ART interruption)
- Willing to be vaccinated against COVID-19 before ART interruption.
Exclusion Criteria:
- Participation in any other clinical trial requiring additional blood sampling Participation in an observational study without additional blood sampling is permitted
- Participants in whom condom use or PrEP use by the partner will be difficult or impossible
- Pregnant or breastfeeding patient
- Participants under guardianship or curatorship
- Any condition or infection, including HCV, HBV, SARS-CoV-2 (SARS-CoV-2 PCR positive for less than 72 hours) or known M. tuberculosis active infection History of ischemic heart disease (myocardial infarction, stable or unstable angina, stroke)
- Current or past history of cancer, excluding squamous cell skin cancers
- History or acute known inflammatory ophthalmic affection (uveitis, choroiditis, optic neuropathy)
- Any medical condition that contraindicates ART interruption
- Concomitant or previous conditions that preclude injection of monoclonal antibodies
- History of systemic corticosteroids, immunosuppressive and anti-cancer medications within the last 6 months
- History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions
- Individuals with any contraindication (including hypersensitivity reaction) to 3BNC117-LS and 10-1074-LS infusion
- Prothrombin < 50%
- Creatinine clearance < 60mL/mn (Cockroft)
- ASAT or ALAT or bilirubine (total et conjugated) ≥ 10 times the upper limit of normal
- Patient with an isolated HIV-2 viral strain
- Planned absence that could affect participation in the trial (travel abroad, relocation, impending transfer...)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05300035
Contact: Mathilde Ghislain, MSc | +331 45 59 52 29 | mathilde.ghislain@inserm.fr | |
Contact: Nicolas Leturque, MSc | +331 45 59 51 93 | nicolas.leturque@inserm.fr |

Principal Investigator: | Cécile Goujard, Pr | Assistance Publique - Hôpitaux de Paris |
Responsible Party: | ANRS, Emerging Infectious Diseases |
ClinicalTrials.gov Identifier: | NCT05300035 |
Other Study ID Numbers: |
ANRS 176 RHIVIERA-02 |
First Posted: | March 29, 2022 Key Record Dates |
Last Update Posted: | February 1, 2023 |
Last Verified: | January 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Infections Communicable Diseases Disease Attributes Pathologic Processes |
Antibodies Antibodies, Monoclonal Immunologic Factors Physiological Effects of Drugs |